PlumX Metrics
Embed PlumX Metrics

Risk and Protective Factors for Sudden Cardiac Death: An Umbrella Review of Meta-Analyses

Frontiers in Cardiovascular Medicine, ISSN: 2297-055X, Vol: 9, Page: 848021
2022
  • 6
    Citations
  • 0
    Usage
  • 53
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

Recent Findings in Heart Failure Described by Researchers from Linkoping University (Risk and Protective Factors for Sudden Cardiac Death: an Umbrella Review of Meta-analyses)

2023 FEB 02 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- Current study results on Heart Disorders and Diseases -

Review Description

Background: Sudden cardiac death (SCD) is a global public health issue, accounting for 10–20% of deaths in industrialized countries. Identification of modifiable risk factors may reduce SCD incidence. Methods: This umbrella review systematically evaluates published meta-analyses of observational and randomized controlled trials (RCT) for the association of modifiable risk and protective factors of SCD. Results: Fifty-five meta-analyses were included in the final analysis, of which 31 analyzed observational studies and 24 analyzed RCTs. Five associations of meta-analyses of observational studies presented convincing evidence, including three risk factors [diabetes mellitus (DM), smoking, and early repolarization pattern (ERP)] and two protective factors [implanted cardiac defibrillator (ICD) and physical activity]. Meta-analyses of RCTs identified five protective factors with a high level of evidence: ICDs, mineralocorticoid receptor antagonist (MRA), beta-blockers, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with HF. On the contrary, other established, significant protective agents [i.e., amiodarone and statins along with angiotensin-converting enzyme (ACE) inhibitors in heart failure (HF)], did not show credibility. Likewise, risk factors as left ventricular ejection fraction in HF, and left ventricular hypertrophy, non-sustain ventricular tachycardia, history of syncope or aborted SCD in pediatric patients with hypertrophic cardiomyopathy, presented weak or no evidence. Conclusions: Lifestyle risk factors (physical activity, smoking), comorbidities like DM, and electrocardiographic features like ERP constitute modifiable risk factors of SCD. Alternatively, the use of MRA, beta-blockers, SGLT-2 inhibitors, and ICD in patients with HF are credible protective factors. Further investigation targeted in specific populations will be important for reducing the burden of SCD. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020216363, PROSPERO CRD42020216363.

Bibliographic Details

Tsartsalis, Dimitrios; Korela, Dafni; Karlsson, Lars O; Foukarakis, Emmanouil; Svensson, Anneli; Anastasakis, Aris; Venetsanos, Dimitrios; Aggeli, Constantina; Tsioufis, Costas; Braunschweig, Frieder; Dragioti, Elena; Charitakis, Emmanouil

Frontiers Media SA

Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know